AU2003212245A1 - Method of diagnosis of inflammatory diseases using calgranulin c - Google Patents

Method of diagnosis of inflammatory diseases using calgranulin c

Info

Publication number
AU2003212245A1
AU2003212245A1 AU2003212245A AU2003212245A AU2003212245A1 AU 2003212245 A1 AU2003212245 A1 AU 2003212245A1 AU 2003212245 A AU2003212245 A AU 2003212245A AU 2003212245 A AU2003212245 A AU 2003212245A AU 2003212245 A1 AU2003212245 A1 AU 2003212245A1
Authority
AU
Australia
Prior art keywords
calgranulin
diagnosis
inflammatory diseases
inflammatory
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003212245A
Other languages
English (en)
Other versions
AU2003212245A8 (en
Inventor
Johannes Roth
Clemens Sorg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Switch Biotech AG
Original Assignee
Switch Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Switch Biotech AG filed Critical Switch Biotech AG
Publication of AU2003212245A1 publication Critical patent/AU2003212245A1/en
Publication of AU2003212245A8 publication Critical patent/AU2003212245A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2003212245A 2002-02-15 2003-02-17 Method of diagnosis of inflammatory diseases using calgranulin c Abandoned AU2003212245A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/077,600 US20030175713A1 (en) 2002-02-15 2002-02-15 Method for diagnosis of inflammatory diseases using CALGRANULIN C
US10/077,600 2002-02-15
PCT/EP2003/001575 WO2003069341A2 (en) 2002-02-15 2003-02-17 Method of diagnosis of inflammatory diseases using calgranulin c

Publications (2)

Publication Number Publication Date
AU2003212245A1 true AU2003212245A1 (en) 2003-09-04
AU2003212245A8 AU2003212245A8 (en) 2003-09-04

Family

ID=27732684

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003212245A Abandoned AU2003212245A1 (en) 2002-02-15 2003-02-17 Method of diagnosis of inflammatory diseases using calgranulin c

Country Status (8)

Country Link
US (3) US20030175713A1 (cg-RX-API-DMAC7.html)
EP (1) EP1474689B1 (cg-RX-API-DMAC7.html)
JP (2) JP5487404B2 (cg-RX-API-DMAC7.html)
AU (1) AU2003212245A1 (cg-RX-API-DMAC7.html)
CA (1) CA2474890A1 (cg-RX-API-DMAC7.html)
DK (1) DK1474689T3 (cg-RX-API-DMAC7.html)
ES (1) ES2394962T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003069341A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C
JP2006511790A (ja) * 2002-11-14 2006-04-06 サイファージェン バイオシステムズ インコーポレイテッド 羊膜内炎症のためのバイオマーカー
WO2005064307A2 (en) 2003-12-23 2005-07-14 Roche Diagnostics Gmbh Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
JP4868378B2 (ja) * 2004-11-19 2012-02-01 株式会社明治 炎症性腸疾患治療薬
ES2347485T3 (es) * 2006-05-19 2010-10-29 F. Hoffmann-La Roche Ag Uso de la proteina s100a12, como marcador para el cancer colorrectal.
DE102007036678B4 (de) * 2007-08-03 2015-05-21 Sirs-Lab Gmbh Verwendung von Polynukleotiden zur Erfassung von Genaktivitäten für die Unterscheidung zwischen lokaler und systemischer Infektion
US20110184712A1 (en) * 2007-10-11 2011-07-28 Cardiodx, Inc. Predictive models and methods for diagnosing and assessing coronary artery disease
EP2210102A2 (en) * 2007-10-19 2010-07-28 Erac As Edta resistant s100a12 complexes (erac)
GB0922006D0 (en) * 2009-12-17 2010-02-03 Genome Res Ltd Diagnostic
WO2011146479A1 (en) * 2010-05-18 2011-11-24 The Texas A&M University System Method and composition for the diagnosis and monitoring of inflammatory diseases
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
CA2838284C (en) * 2011-06-04 2017-10-24 Rochester General Hospital Research Institute Methods relating to s100a12 for diagnosing infectious diseases and kit therefor
WO2013167727A2 (en) 2012-05-11 2013-11-14 Westfaelische Wilhelms-Universitaet Muenster Method for determining arthritis relapse risk
US11267854B2 (en) 2016-07-20 2022-03-08 Westfaelische Wilhelms-Universitaet Muenster Complex-specific standardization of immunological methods for the quantification of S100A12
US11287396B2 (en) 2020-06-05 2022-03-29 Princeton Biochemicals, Inc. Method and system for simultaneous determination of multiple measurable biomarkers during the development of a communicable disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
JPH08238090A (ja) * 1995-03-06 1996-09-17 Jiro Hitomi 新規カルシウム結合タンパク
JPH08238091A (ja) * 1995-03-06 1996-09-17 Jiro Hitomi 新規カルシウム結合タンパク
EP0731166A3 (en) * 1995-03-06 1997-12-29 Tonen Corporation Novel calcium-binding proteins
US5976832A (en) * 1995-03-06 1999-11-02 Tonen Corporation DNA encoding novel calcium-binding proteins
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6028060A (en) * 1997-01-29 2000-02-22 Vanderbilt University Treatment of chronic inflammatory diseases with CM101/GBS toxin
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
AU2001259710A1 (en) * 2000-05-09 2001-11-20 Genetics Institute, Llc Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
WO2002033377A2 (en) * 2000-09-20 2002-04-25 Surromed, Inc. Biological markers for evaluating therapeutic treatment of inflammatory and autoimmune disorders
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
US20030175713A1 (en) * 2002-02-15 2003-09-18 Clemens Sorg Method for diagnosis of inflammatory diseases using CALGRANULIN C

Also Published As

Publication number Publication date
US20170138931A9 (en) 2017-05-18
WO2003069341A2 (en) 2003-08-21
ES2394962T3 (es) 2013-02-07
EP1474689B1 (en) 2012-09-12
DK1474689T3 (da) 2012-12-03
JP5650985B2 (ja) 2015-01-07
EP1474689A2 (en) 2004-11-10
WO2003069341A3 (en) 2004-02-05
JP2011053222A (ja) 2011-03-17
AU2003212245A8 (en) 2003-09-04
JP5487404B2 (ja) 2014-05-07
US20050147972A1 (en) 2005-07-07
US20100311758A1 (en) 2010-12-09
CA2474890A1 (en) 2003-08-21
JP2005517414A (ja) 2005-06-16
US20030175713A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
AU2003219689A1 (en) Method and system for risk-modulated diagnosis of disease
AU2003224414A1 (en) Acoustic diagnosis of sinusitis
EP1571970A3 (en) Diagnosis and monitoring of diseases
AU2003301347A1 (en) Methods for monitoring treatment of disease
AU2003252543A1 (en) Method of microelectrode connection and connected structure of use threof
AU2003212245A8 (en) Method of diagnosis of inflammatory diseases using calgranulin c
AU2003247827A1 (en) Methods to assess quality of microarrays
AU2003277596A1 (en) Method of deuterization
AU2003248594A1 (en) Method of examining an object by means of elastography
AU2003212246A1 (en) Method for diagnosis of inflammatory diseases using mrp8/mrp14
AU2003206272A1 (en) Method of image analysis
AUPS096002A0 (en) Method of construction
AU2003280824A1 (en) Method of organ regeneration
AU2003254895A1 (en) Method of judging inflammatory disease
AU2003283732A1 (en) Method of tomographic imaging
AU2003294206A1 (en) Methods for diagnosing htlv-i-mediated diseases
AU2003251650A1 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
AU2003220903A1 (en) Method of judging risk of peiodontal disease
AU2003900639A0 (en) Novel method of treating inflammatory diseases
AU2003207273A1 (en) Method of examining allergic disease
AU2003232744A1 (en) Methods for predicting fatty acid enrichment
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2003263728A1 (en) Method for diagnosis of cancer
AU2003290512A1 (en) Method of weldbonding
AU2003235111A1 (en) Method of evaluating blood compatibility

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase